EQS-Adhoc

Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Mergers &
Acquisitions
Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes
its Board of Directors and appoints Executive Officers

08.01.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd.,
constitutes its Board of Directors and appoints Executive Officers

Schlieren (Zurich), Switzerland, January 8, 2016 - Cytos Biotechnology Ltd
("Cytos" or the "Company" - to be renamed Kuros Biosciences Ltd.),
announced today that the Board of Directors has constituted itself with Dr.
Christian Itin stepping down as CEO but remaining as Chairman of the Board
and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of the
Board. Further, the newly constituted Board elected Didier Cowling as Chief
Executive Officer, Dr. Alistair Irvine as Chief Business Officer, Dr. Jason
Schense as Chief Technology Officer and confirmed Harry Welten as the Chief
Financial Officer. All appointments are effective upon closing of the
acquisition of Kuros Biosurgery Holding AG which is expected to take place
within the next few weeks.

"Yesterday, Cytos has received overwhelming support by our shareholders for
the acquisition of Kuros Biosurgery Ltd. With the closing of the
transaction most existing members of the Board will step down and new
members of the Board of Directors have been elected. I would like to thank
the outgoing Board members for their continued support and welcome the new
members of the board and executive management", commented Christian Itin,
Chairman of Cytos. "We are pleased that Harry Welten will continue as Chief
Financial Officer and are looking forward to forming Kuros Biosciences".

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: [phone]
[e-mail]

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

www.cytos.com

End of ad hoc announcement

+++++
Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=XGGVUXDFGF
Document title: Cytos_160108

---------------------------------------------------------------------------

08.01.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------------


Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Valor: -
Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart;
Open Market in Frankfurt ; SIX


End of News EQS Group News Service
---------------------------------------------------------------------------

427737 08.01.2016